FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2245506455> ?p ?o ?g. }

• W2245506455 endingPage "14625" @default.
• W2245506455 startingPage "14625" @default.
• W2245506455 abstract "14625 Background: Sunitinib (SU) is a multi target tyrosine kinase inhibitor approved by FDA and EMEA in Renal Cell Cancer (RCC) and Gastric intestinal stromal tumor (GIST). SU has not been reported to increase the rate of VTEs in RCC, GIST. VTEs’ management and outcome under SU treatment is unknown. We reviewed cases of VTEs in RCC, GIST and NSCLC pts treated with SU. Methods: RCC, GIST and NSCLC pts treated with SU in prospective clinical trials at Institut Gustave Roussy (IGR) were analyzed to assess the risk of VTEs rate and identify predisposing factors. SU was given at 50 mg/d 4 wks out of 6, as a 2nd or 3rd line in GIST, as maintenance therapy after 4 cycles of paclitaxel-carboplatin in NSCLC and in RCC pts after cytokine failure. Key exclusions criteria of these trials were: pts with history of thrombosis within 6 months, brain metastasis, PS WHO>1, or squamous cell lung cancer. Diagnoses of symptomatic pulmonary embolism (PE) confirmed by CT pulmonary angiography were centrally reviewed. Results: Between Aug.05 and Oct.06, 72 pts were included (21 GIST, 8 NSCLC, 43 RCC). Baseline characteristics were (RCC/GIST/NSCLC): female 23%/57%/50%, mean age 54/54/51yrs, PS 0: 84%/57%/38%, indwelling central venous catheters (ICVC) 0%/0%/100%, bone metastases: 11%/0%/75%, liver metastases: 76 %/28%/37%. None has history of previous cancer or surgery within 1 yr. Five pts (6.9%, 95%CI: 3.0–15.2%) developed symptomatic PE., 3 in NSCLC pts (37%), 1 in RCC (2%) and 1 in GIST (5%). PE occurred early aftersunitinib initiation (4 wks in 2 pts, 6 wks in 2 pts, 10 wks in 1 pt). In case of PE, SU was interrupted in NSCLC but continued in GIST and RCC pts. All 5 PE were treated with low molecular weight heparin (LMWH). In 1 pt (GIST), LMWH was discontinued after 4 months due to a grade 3 esophageal hemorrhage (peptic esophagitis) but SU was maintained for 3 additional months untill disease progression. In 1 pt (RCC), LMWH and SU were maintained for up to 24 months. Conclusions: The incidence of symptomatic PE among pts treated with SU was within the expected range for cancer patients receiving chemotherapy, but PE occurred early after SU initiation. Concomitant SU and LMWH treatment is feasible but might expose to severe hemorrhage. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer Oncology Pfizer Oncology" @default.
• W2245506455 created "2016-06-24" @default.
• W2245506455 creator A5006010044 @default.
• W2245506455 creator A5010191505 @default.
• W2245506455 creator A5020761970 @default.
• W2245506455 creator A5030914311 @default.
• W2245506455 creator A5034189406 @default.
• W2245506455 creator A5049799682 @default.
• W2245506455 creator A5082289340 @default.
• W2245506455 creator A5089666818 @default.
• W2245506455 date "2008-05-20" @default.
• W2245506455 modified "2023-09-27" @default.
• W2245506455 title "Management and outcome of venous thromboembolic events (VTEs) during sunitinib treatment" @default.
• W2245506455 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.14625" @default.
• W2245506455 hasPublicationYear "2008" @default.
• W2245506455 type Work @default.
• W2245506455 sameAs 2245506455 @default.
• W2245506455 citedByCount "0" @default.
• W2245506455 crossrefType "journal-article" @default.
• W2245506455 hasAuthorship W2245506455A5006010044 @default.
• W2245506455 hasAuthorship W2245506455A5010191505 @default.
• W2245506455 hasAuthorship W2245506455A5020761970 @default.
• W2245506455 hasAuthorship W2245506455A5030914311 @default.
• W2245506455 hasAuthorship W2245506455A5034189406 @default.
• W2245506455 hasAuthorship W2245506455A5049799682 @default.
• W2245506455 hasAuthorship W2245506455A5082289340 @default.
• W2245506455 hasAuthorship W2245506455A5089666818 @default.
• W2245506455 hasConcept C121608353 @default.
• W2245506455 hasConcept C126322002 @default.
• W2245506455 hasConcept C141071460 @default.
• W2245506455 hasConcept C143998085 @default.
• W2245506455 hasConcept C16930146 @default.
• W2245506455 hasConcept C2775922572 @default.
• W2245506455 hasConcept C2776256026 @default.
• W2245506455 hasConcept C2776265017 @default.
• W2245506455 hasConcept C2777472916 @default.
• W2245506455 hasConcept C2779490328 @default.
• W2245506455 hasConcept C2780011451 @default.
• W2245506455 hasConcept C2780868729 @default.
• W2245506455 hasConcept C71924100 @default.
• W2245506455 hasConcept C90924648 @default.
• W2245506455 hasConceptScore W2245506455C121608353 @default.
• W2245506455 hasConceptScore W2245506455C126322002 @default.
• W2245506455 hasConceptScore W2245506455C141071460 @default.
• W2245506455 hasConceptScore W2245506455C143998085 @default.
• W2245506455 hasConceptScore W2245506455C16930146 @default.
• W2245506455 hasConceptScore W2245506455C2775922572 @default.
• W2245506455 hasConceptScore W2245506455C2776256026 @default.
• W2245506455 hasConceptScore W2245506455C2776265017 @default.
• W2245506455 hasConceptScore W2245506455C2777472916 @default.
• W2245506455 hasConceptScore W2245506455C2779490328 @default.
• W2245506455 hasConceptScore W2245506455C2780011451 @default.
• W2245506455 hasConceptScore W2245506455C2780868729 @default.
• W2245506455 hasConceptScore W2245506455C71924100 @default.
• W2245506455 hasConceptScore W2245506455C90924648 @default.
• W2245506455 hasIssue "15_suppl" @default.
• W2245506455 hasLocation W22455064551 @default.
• W2245506455 hasOpenAccess W2245506455 @default.
• W2245506455 hasPrimaryLocation W22455064551 @default.
• W2245506455 hasRelatedWork W1942066213 @default.
• W2245506455 hasRelatedWork W2048472087 @default.
• W2245506455 hasRelatedWork W2075996664 @default.
• W2245506455 hasRelatedWork W2129878459 @default.
• W2245506455 hasRelatedWork W2329296740 @default.
• W2245506455 hasRelatedWork W2397084084 @default.
• W2245506455 hasRelatedWork W2463152737 @default.
• W2245506455 hasRelatedWork W4236647915 @default.
• W2245506455 hasRelatedWork W4285598862 @default.
• W2245506455 hasRelatedWork W4290193190 @default.
• W2245506455 hasVolume "26" @default.
• W2245506455 isParatext "false" @default.
• W2245506455 isRetracted "false" @default.
• W2245506455 magId "2245506455" @default.
• W2245506455 workType "article" @default.